Subjective Versus Objective Outcomes of Antipsychotics for the Treatment of Neuropsychiatric Symptoms Associated with DementiaVredeveld, E. J., Hulshof, T. A., Zuidema, S. U. & Luijendijk, H. J., Sep-2019, In : Cns Drugs. 33, 9, p. 933-942 10 p.
Research output: Contribution to journal › Article › Academic › peer-review
Background Knowledge about treatment status can influence effects measured in trials when subjective scales are used. Objective The aim of this study was to compare subjective outcomes with objective outcomes of conventional and atypical antipsychotics for neuropsychiatric symptoms (NPS) in dementia. Methods We performed a meta-epidemiological study of 38 randomized, placebo-controlled trials. For effectiveness, we used change in NPS and response rate as subjective outcomes, while overall dropout and additional psychotropic use were used as objective outcomes. For side effects, extrapyramidal symptoms (EPS) and somnolence were used as subjective outcomes, while dropout due to adverse events, medication use for EPS, and participants falling were used as objective outcomes. Results Conventional antipsychotics reduced NPS more than placebo (standardized mean difference [SMD] - 0.36, 95% confidence interval [CI] - 0.49 to - 0.23), as did atypical antipsychotics (SMD - 0.14, 95% CI - 0.19 to - 0.08). Response rates in the drug groups were also higher. Overall dropout did not differ between conventional antipsychotics and placebo (odds ratio [OR] 1.03, 95% CI 0.77-1.37) or atypical antipsychotics and placebo (OR 1.01, 95% CI 0.89-1.14). Furthermore, additional psychotropic use did not differ. The risk of EPS was higher for conventional (OR 2.93, 95% CI 2.04-4.22) and atypical antipsychotics (OR 1.52, 95% CI 1.23-1.88) versus placebo, as was the risk of somnolence and dropout due to adverse events, but medication use for EPS, as well as risk of falls, was not. Conclusions The effectiveness of antipsychotics for NPS in dementia based on subjective scales was not confirmed using objective outcomes, in contrast to the increased risk of side effects.
|Number of pages||10|
|Publication status||Published - Sep-2019|
- ACUTELY AGITATED PATIENTS, PLACEBO-CONTROLLED TRIAL, NURSING-HOME PATIENTS, DOUBLE-BLIND, ALZHEIMERS-DISEASE, BEHAVIORAL DISTURBANCES, PSYCHOLOGICAL SYMPTOMS, GERIATRIC-PATIENTS, ATYPICAL ANTIPSYCHOTICS, NONPSYCHOTIC PATIENTS